MicroMatrix® Flex in Tunneling Wounds

Key facts

Sponsor

Integra LifeSciences Corporation

Principal Investigator

Claire Witherel, Ph.D.

Integra LifeSciences Corporation

Intervention

MicroMatrix® Flex(device)

Enrollment

25 target

Eligibility

22 years · All sexes

Timeline

2024 – 2025

Study locations (3)

• University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
• MedStar Health Research Institute Inc., Washington D.C., District of Columbia, United States
• Northwell Comprehensive Wound Healing Center, Lake Success, New York, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Necrotizing soft tissue infection

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONNCT07107555
  Necrotizing Soft Tissue Infections
  European Society for Trauma and Emergency Surgery
• RECRUITINGNANCT07120386
  Irrigating vs Traditional Negative Pressure Wound Therapy to Treat Necrotizing Soft Tissue Infections
  HealthPartners Institute
• RECRUITINGNANCT06857708
  The Management of Necrotizing Soft Tissue Infection Wounds With Cytal® Wound Matrix and MicroMatrix®
  Benjamin T. Miller
• RECRUITINGNANCT03482245
  The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
  Washington University School of Medicine
• RECRUITINGNCT06002607
  Shorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue Infections
  University of California, Irvine
• RECRUITINGNCT07359651
  FATAL-NSTI Study (Factors Associated With In-hospital mortALity in NSTI).
  University of Cagliari

See all trials for Necrotizing soft tissue infection →